COPD and Inflammatory Mediators

COPD Clinical Trial

Official title:

Comparison of Exercise Training

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04271124
• Other study ID #: Effect of exercise training
• Status: Recruiting
• Phase: N/A
• Start date: May 2020
• Est. completion date: July 2020

Study information

• Verified date: January 2020
• Source: Faculty of Medicine, Sousse
• Contact: Amal Acheche, PhD
• Phone: 00216 55028619
• Email: acheche_amal[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020.

Description:

COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversible.Not only the long-term exposition to noxious particles and gases contributes to the development of COPD, but also many others factors such as genetics and cigarette smoking. Cigarettes are harmful and contribute to different extra pulmonary disorders. Although COPD affects lungs some extrapulmonary manifestations are prescribed such as muscle dysfunction, abnormal respiratory muscles and systemic inflammation. Indeed, the systemic inflammation[6, 8] is considered as a key process in the pathogenesis of COPD. It involves different cells and molecules; high levels of circulating of white blood cells, increased plasma c-reactive proteins (CRP), interleukin 6 (Il6) have been reported in.those patients.Likewise, systemic inflammation could worsen the comorbidities (cardiovascular, osteoporosis..) and may lead to the exercise limitation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: July 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• COPD diagnosed by pulmonary function testing

• Clinically stable

• Abscence of other obstructive diseases

• Signed written consent

Exclusion Criteria:

• Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions

• cardiovascular diseases.

• Contre-indications to physical therapy

• Acute exacerbations a month before the intervention

Related Conditions & MeSH terms

• COPD

Intervention

Other:
• exercise training
The patients are allocated to PR+ET group or PR Each group receive an exercise training

Locations

Country	Name	City	State
Tunisia	Laboratoire de Recherche : Physiologie de l'Exercice et Physiopathologie	Sousse

Sponsors (1)

Lead Sponsor	Collaborator
Faculty of Medicine, Sousse

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Interleukins concentrations	ELISA assay	Before the training, 2 months
Secondary	6Minutes Walk test	patients performed the test	Before the training, 2 months